KEGG   DRUG: Cevostamab
Entry
D11984                      Drug                                   
Name
Cevostamab (USAN/INN)
Formula
C6508H10063N1727O2027S40
Exact mass
146121.6269
Mol weight
146211.56
Sequence
(A chain)
EVQLVESGPG LVKPSETLSL TCTVSGFSLT RFGVHWVRQP PGKGLEWLGV IWRGGSTDYN
AAFVSRLTIS KDNSKNQVSL KLSSVTAADT AVYYCSNHYY GSSDYALDNW GQGTLVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYG
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE
MTKNQVSLWC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
(B chain)
EVQLVQSGAE VKKPGASVKV SCKASGFTFT SYYIHWVRQA PGQGLEWIGW IYPENDNTKY
NEKFKDRVTI TADTSTSTAY LELSSLRSED TAVYYCARDG YSRYYFDYWG QGTLVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYGS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSREEM
TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLVS KLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(C chain)
DIQMTQSPSS LSASVGDRVT ITCKASQDVR NLVVWFQQKP GKAPKLLIYS GSYRYSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ HYSPPYTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(D chain)
DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSRTRKNYLA WYQQKPGQSP KLLIYWTSTR
KSGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCKQSFIL RTFGQGTKVE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: A22-A95, A147-A203, A223-D214, A229-B228, A232-B231, A264-A324, A370-A428, B22-B96, B146-B202, B222-C219, B263-B323, B369-B427, C23-C94, C139-C199, D23-D88, D134-D194)
  Type
Peptide
Efficacy
Antineoplastic
  Type
Monoclonal antibody, bispecific antibody
Target
FCRL5 [HSA:83416] [KO:K06727]
CD3E [HSA:916] [KO:K06451]
Brite
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD3E
     D11984  Cevostamab (USAN/INN)
 Not elsewhere classified
  Organismal systems
   Immune system
    FCRL5
     D11984  Cevostamab (USAN/INN)
Other DBs
CAS: 2249888-53-5
PubChem: 497620397
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system